Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2009-10-01
2011-10-04
Saidha, Tekchand (Department: 1652)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S199000
Reexamination Certificate
active
08029782
ABSTRACT:
The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
REFERENCES:
patent: 4424311 (1984-01-01), Nagaoka
patent: 4708930 (1987-11-01), Kortright
patent: 4743543 (1988-05-01), Kortright
patent: 4892935 (1990-01-01), Yoshida
patent: 4914021 (1990-04-01), Toth
patent: 4918164 (1990-04-01), Hellstrom
patent: 4921789 (1990-05-01), Salem
patent: 4921790 (1990-05-01), O'brien
patent: 4939240 (1990-07-01), Chu
patent: 4963484 (1990-10-01), Kufe
patent: 5053489 (1991-10-01), Kufe
patent: 5096815 (1992-03-01), Ladner
patent: 5110911 (1992-05-01), Samuel
patent: 5198346 (1993-03-01), Ladner
patent: 5200182 (1993-04-01), Kiczka
patent: 5223409 (1993-06-01), Ladner
patent: 5270163 (1993-12-01), Gold
patent: 5270204 (1993-12-01), Vallee
patent: 5286487 (1994-02-01), Vallee
patent: 5286637 (1994-02-01), Veronese
patent: 5359030 (1994-10-01), Ekwuribe
patent: 5389537 (1995-02-01), Raines
patent: 5446090 (1995-08-01), Harris
patent: 5475096 (1995-12-01), Gold
patent: 5512443 (1996-04-01), Schlom
patent: 5545530 (1996-08-01), Satomura
patent: 5559212 (1996-09-01), Ardelt
patent: 5562907 (1996-10-01), Arnon
patent: 5660827 (1997-08-01), Thorpe
patent: 5672662 (1997-09-01), Harris
patent: 5693763 (1997-12-01), Codington
patent: 5733731 (1998-03-01), Schatz
patent: 5739208 (1998-04-01), Harris
patent: 5786457 (1998-07-01), Nett
patent: 5808005 (1998-09-01), Codington
patent: 5811238 (1998-09-01), Stemmer
patent: 5824544 (1998-10-01), Armentano
patent: 5824784 (1998-10-01), Kinstler
patent: 5830721 (1998-11-01), Stemmer
patent: 5830730 (1998-11-01), German
patent: 5837458 (1998-11-01), Minshull
patent: 5840296 (1998-11-01), Raines
patent: 5840840 (1998-11-01), Rybak
patent: 5855866 (1999-01-01), Thorpe
patent: 5866119 (1999-02-01), Bandman
patent: 5872154 (1999-02-01), Wilson
patent: 5885808 (1999-03-01), Spooner
patent: 5892019 (1999-04-01), Schlom
patent: 5892020 (1999-04-01), Mezes
patent: 5900461 (1999-05-01), Harris
patent: 5932462 (1999-08-01), Harris
patent: 5955073 (1999-09-01), Rybak
patent: 5981225 (1999-11-01), Kochanek
patent: 5990237 (1999-11-01), Bentley
patent: 5994106 (1999-11-01), Kovesdi
patent: 5994128 (1999-11-01), Fallaux
patent: 5994132 (1999-11-01), Chamberlain
patent: 6001557 (1999-12-01), Wilson
patent: 6019978 (2000-02-01), Ertl
patent: 6033908 (2000-03-01), Bout
patent: 6045793 (2000-04-01), Rybak
patent: 6051230 (2000-04-01), Thorpe
patent: 6077499 (2000-06-01), Griffiths
patent: 6083477 (2000-07-01), Goldenberg
patent: 6183744 (2001-02-01), Goldenberg
patent: 6197528 (2001-03-01), Wu
patent: 6214966 (2001-04-01), Harris
patent: 6271369 (2001-08-01), Torrence
patent: 6280991 (2001-08-01), Raines
patent: 6312694 (2001-11-01), Thorpe
patent: 6348558 (2002-02-01), Harris
patent: 6362254 (2002-03-01), Harris
patent: 6362276 (2002-03-01), Harris
patent: 6395276 (2002-05-01), Rybak
patent: 6399068 (2002-06-01), Goldenberg
patent: 6406897 (2002-06-01), Kim et al.
patent: 6416758 (2002-07-01), Thorpe
patent: 6428785 (2002-08-01), Gokcen
patent: 6432397 (2002-08-01), Harris
patent: 6437025 (2002-08-01), Harris
patent: 6448369 (2002-09-01), Bentley
patent: 6515100 (2003-02-01), Harris
patent: 6541543 (2003-04-01), Harris
patent: 6541619 (2003-04-01), Park
patent: 6610281 (2003-08-01), Harris
patent: 6649393 (2003-11-01), Youle
patent: 6653104 (2003-11-01), Goldenberg
patent: 6664331 (2003-12-01), Harris
patent: 6676941 (2004-01-01), Thorpe
patent: 6737505 (2004-05-01), Bentley
patent: 6828401 (2004-12-01), Nho
patent: 6838076 (2005-01-01), Patton
patent: 6864327 (2005-03-01), Bentley
patent: 6864350 (2005-03-01), Harris
patent: 6894025 (2005-05-01), Harris
patent: 6962702 (2005-11-01), Hansen
patent: 7033572 (2006-04-01), Goldenberg
patent: 7125541 (2006-10-01), Thorpe
patent: 7199223 (2007-04-01), Bossard
patent: 7416875 (2008-08-01), Raines
patent: 7476725 (2009-01-01), Zaplisky
patent: 2001/0049434 (2001-12-01), Conklin
patent: 2002/0048550 (2002-04-01), Vallera
patent: 2003/0114368 (2003-06-01), Rybak
patent: 2003/0219785 (2003-11-01), Hallahan
patent: 2005/0158273 (2005-07-01), Harris
patent: 2005/0181449 (2005-08-01), Kozlowski
patent: 2005/0261232 (2005-11-01), Strong et al.
patent: 2006/0292137 (2006-12-01), Raines
patent: 2007/0166278 (2007-07-01), Veronese
patent: 2008/0025964 (2008-01-01), Kink
patent: 2008/0095755 (2008-04-01), Kink
patent: WO 97/38134 (1997-10-01), None
patent: WO 98/33941 (1998-08-01), None
patent: WO 99/02685 (1999-01-01), None
patent: WO 99/07724 (1999-02-01), None
patent: WO 00/09675 (2000-02-01), None
patent: WO 00/12738 (2000-03-01), None
patent: 0031242 (2000-06-01), None
patent: WO 02/02630 (2002-01-01), None
patent: WO 03/031581 (2002-04-01), None
patent: 2007149594 (2007-12-01), None
Kozlowski A, et al., “Development of pegylated interferons for the treatment of chronic hepatitis C.” 2001 BioDrugs, 15:419-429.
Domachowske et al., “Evolution of antiviral activity in the ribonuclease a gene superfamily . . . ,”Nucleic Acids Res 26 (23): 5327-32 (1998).
Sorrentino and Glitz, “Ribonuclease activity and substrate preference of human eosinophil cationic protein (ECP)”1991 FEBS Lett. 288:23-6.
Hamachi et al., “Design and semisynthesis of spermine-sensitive ribonucleases S” 1999 Bioorg Med Chem Lett 9:1215-1218.
Goldberg and Baldwin, “A specific transition state for S-peptide combining with folded S-protein and then refolding,” 1999 PNAS 96:2019-2024.
Asai, T. et al., “An interaction between S tag and S protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery,” 2005 J Immun Meth, 299:63-76.
Backer M et al., “Adapter Protein for Site-Specific conjugation of Payloads for Targeted Drug Delivery,” 2004 Bioconjugate Chem 15:1021-1029.
Backer, M.V. et al., 2003, “Humanized docking system for assembly of targeting drug delivery complexes,” J Cont Release, 89:499-511.
Zalipsky, “Functionalized Poly(ethylene glycol) for Preparation of Biologically Relevant Conjugates,” Bioconjugate Chem 6, 150-165 (1995).
Kinstler et al., “Mono-N-terminal poly(ethylene glycol)—protein conjugates,” 2002 Advanced Drug Delivery Reviews 54:477-485.
Roberts et al. “Chemistry for peptide and protein PEGylation,” 2002 Advanced Drug Delivery Reviews 54:459-476.
Miller, K.D. And Sledge, G.W. Jr, “Taxanes in the treatment of breast cancer: a prodigy comes of age,”1999 Cancer Investigation, 17:121-136.
Haldar et al., “BcI2 Is the Guardian of Microtubule Integrity,” 1997 Cancer Research 57:229-233.
Lanni et al., “p53-independent apoptosis induced by paclitaxel through an indirect mechanism,” 1997 Proc Natl Acad Sci 94:9679-9683.
Tortora et al., “Synergistic Inhibition of Growth and Induction of Apoptosis by 8-Chloro-cAMP and Paclitaxel or Cisplatin in Human Cancer Cells,” 1997 Cancer Res 57:5107-5111.
Zaffaroni et al., “Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and—resistant human ovarian cancer cells,” 1998 Brit. J. Cancer 77:1378-1385.
Ottl et al., “Preparation and Photoactivation of Caged Fluorophores and Caged Proteins Using a New Class of Heterobifunctional, Photocleavable Cross-Linking Reagents,”1998 Bioconj Chem 9:143-151.
Vasey et al., “Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl) methacrylamide Copolymer Doxorubicin] . . . ,” 1999 Clin Cancer Res 5:83-94.
Capala et al., “Boronated Epidermal Growth Factor as a Potential Targeting Agent for Boron Neutron Capture Therapy of Brain Tumors,” 1996 Bioconjugate Chem 7:7-15.
Press et al., “Expression of the HER-2
eu proto-oncogene in normal human adult and fetal tissues,” 1990 Oncogene 5:953-62.
Pegram et al., Phase II study of intravenous recombinant humanized anti-p185 HER-2 Monoclonal Antibody (rhuMAbHER-2) plus Cisplatin in
Kink John
Klink Tony
Strong Laura
Casimir Jones S.C.
Quintessence Biosciences, Inc.
Saidha Tekchand
LandOfFree
Therapeutic ribonucleases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic ribonucleases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic ribonucleases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4301534